Girentuximab Completed Phase 2 Trials for metastatic Clear Cell Renal Cell Carcinoma (ccRCC) Treatment
Indications | Status | Purpose | Phase |
---|---|---|---|
Completed | Treatment | 2 |
clinicaltrials.gov Identifier | Title | Drugs |
---|---|---|
NCT02002312 | Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer |